Clinical Trial

A Bridging Study of Liposomal Cytarabine-Daunorubicin in Treating Olderly Patients With Treatment-naive High-Risk (Secondary) Acute Myeloid Leukemia

Not Yet Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated December 28, 2023 (before its estimated February 2026 completion). Its status may not reflect the trial's current state.
Summary
The purpose of this bridging study is to determine the efficacy of liposomal cytarabine-daunorubicin for injection compared with cytarabine and daunorubicin in older patients with high-risk (secondary) acute myeloid leukemia.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2023-12-13.
Trial Details
NCT Number NCT06182592
Lead Sponsor CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
Conditions High-risk (Secondary) Acute Myeloid Leukemia
Enrollment 120 participants
Start Date 2024-01
Primary Completion 2026-02 (estimated)
Study Completion 2026-08 (estimated)
Updated on ClinicalTrials.gov 2023-12-28